EMA Denies Authorization for Omeros Drug Narsoplimab
The European Medicines Agency committee issued a negative opinion on the treatment following a data re-examination.
Updated on Oct. 16, 2026 in Healthcare
Live Poll
Do you trust that pharmaceutical companies prioritize patient access in foreign markets during high domestic demand?
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion on the marketing authorization application for narsoplimab. This decision follows a re-examination process prompted by patient-level data submitted by Omeros Corporation in August.
Why it matters
The decision represents a significant regulatory hurdle for Omeros in the European market. Simultaneously, the company is shifting its resources to focus on surging demand for its drug YARTEMLEA in the United States.
Omeros reported second-quarter gross revenue of $32.2 million for YARTEMLEA, representing 190% growth from the first quarter. Following the news, Omeros shares traded 2.61% lower at $18.30.
The players
European Medicines Agency
This is the European Union agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines.
Omeros Corporation
This is a clinical-stage biopharmaceutical company focused on developing small-molecule and protein therapeutics for large-market and orphan indications.
The details
The CHMP convened an eight-member ad hoc expert group, including hematologists and statisticians, to review the drug's application. Omeros has also notified the EMA of its intent to end its compassionate-use program for narsoplimab due to the increasing U.S. demand for YARTEMLEA.
Timeline
June 2026: The CHMP issued its original negative opinion for narsoplimab.
August 2026: Omeros submitted patient-level data for the re-examination process.
October 1, 2026: Medicare's New Technology Add-on Payment for YARTEMLEA took effect.
October 16, 2026: The CHMP issued a negative opinion following the formal re-examination.
Market Landscape
This regulatory outcome highlights the challenges pharmaceutical firms face when navigating the EMA's centralized marketing authorization procedure. Omeros now pivots its commercial strategy toward domestic markets while abandoning the compassionate-use program in Europe.
The decision primarily affects European patients previously accessing narsoplimab through the now-ending compassionate-use program. Investors should note the company's shift in resources toward growing its U.S. commercial revenue streams.
The takeaway
The firm is prioritizing its U.S. market position as it navigates significant regulatory hurdles in Europe. Future growth for the company will depend on the success of upcoming clinical trials in respiratory and pediatric categories.
What happens next
Omeros plans to initiate new clinical studies later this year, focusing on acute respiratory distress syndrome and the prevention of high-risk TA-TMA in pediatric patients.
Further reading
For more on industry developments, visit our Healthcare section.
Live Poll
Do you trust that pharmaceutical companies prioritize patient access in foreign markets during high domestic demand?
